James Revkin, MD, FACC, FACP, FCCP
Internal Medicine, Cardiovascular Medicine
Titles
- Associate Clinical Professor
- Attending Physician: Cardiology Fellows Clinic
Education & Training
- Postdoctoral TraineeCenter for Bioengineering University of Washington (1988)
- FellowYale University School of Medicine (1987)
- ResidentColumbia-Presbyterian Medical Center, New York, NY (1984)
- MDBrown University (1981)
- BAWilliams College, Philosophy/French (1976)
Languages Spoken
- English
- Français (French)
- Español (Spanish)
Additional Information
Board Certifications
- AB of Internal Medicine, Cardiovascular Disease (1987)
- AB of Internal Medicine, Internal Medicine (1984)
Publications
- Bots ML, Taylor AJ, Kastelein JJ, Peters SA, den Ruijter HM, Tegeler CH, Baldassarre D, Stein JH, O'Leary DH, Revkin JH, Grobbee DE. Rate of change in carotid intima-media thickness and vascular events: meta-analyses can not solve all the issues. A point of view. Journal Of Hypertension 2012, 30: 1690-6. PMID: 22895014, DOI: 10.1097/HJH.0b013e32835644dc.
- Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Surrogate endpoints in randomized cardiovascular clinical trials. Fundamental & Clinical Pharmacology 2011, 25: 411-3. PMID: 20698890, DOI: 10.1111/j.1472-8206.2010.00865.x.
- Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacological Reviews 2007, 59: 40-53. PMID: 17329547, DOI: 10.1124/pr.59.1.1.
- Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal Of Medicine 2007, 357: 2109-22. PMID: 17984165, DOI: 10.1056/NEJMoa0706628.
- Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370: 153-160. PMID: 17630038, DOI: 10.1016/S0140-6736(07)61088-5.
- Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The New England Journal Of Medicine 2007, 356: 1620-30. PMID: 17387131, DOI: 10.1056/NEJMoa071359.
- Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. The New England Journal Of Medicine 2007, 356: 1304-16. PMID: 17387129, DOI: 10.1056/NEJMoa070635.
- Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research And Opinion 2007, 23: 885-94. PMID: 17407645, DOI: 10.1185/030079907X182121.
- Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal 2016, 178: 135-44. PMID: 27502861, DOI: 10.1016/j.ahj.2016.05.010.
- Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal Of Medicine 2017, 376: 1517-1526. PMID: 28304227, DOI: 10.1056/NEJMoa1614062.
- Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal Of Medicine 2017, 376: 1527-1539. PMID: 28304242, DOI: 10.1056/NEJMoa1701488.
Patient Care Organizations
Titles
- Associate Clinical Professor
- Attending Physician: Cardiology Fellows Clinic
Education & Training
- Postdoctoral TraineeCenter for Bioengineering University of Washington (1988)
- FellowYale University School of Medicine (1987)
- ResidentColumbia-Presbyterian Medical Center, New York, NY (1984)
- MDBrown University (1981)
- BAWilliams College, Philosophy/French (1976)
Languages Spoken
- English
- Français (French)
- Español (Spanish)
Additional Information
Board Certifications
- AB of Internal Medicine, Cardiovascular Disease (1987)
- AB of Internal Medicine, Internal Medicine (1984)
Publications
- Bots ML, Taylor AJ, Kastelein JJ, Peters SA, den Ruijter HM, Tegeler CH, Baldassarre D, Stein JH, O'Leary DH, Revkin JH, Grobbee DE. Rate of change in carotid intima-media thickness and vascular events: meta-analyses can not solve all the issues. A point of view. Journal Of Hypertension 2012, 30: 1690-6. PMID: 22895014, DOI: 10.1097/HJH.0b013e32835644dc.
- Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Surrogate endpoints in randomized cardiovascular clinical trials. Fundamental & Clinical Pharmacology 2011, 25: 411-3. PMID: 20698890, DOI: 10.1111/j.1472-8206.2010.00865.x.
- Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacological Reviews 2007, 59: 40-53. PMID: 17329547, DOI: 10.1124/pr.59.1.1.
- Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal Of Medicine 2007, 357: 2109-22. PMID: 17984165, DOI: 10.1056/NEJMoa0706628.
- Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370: 153-160. PMID: 17630038, DOI: 10.1016/S0140-6736(07)61088-5.
- Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The New England Journal Of Medicine 2007, 356: 1620-30. PMID: 17387131, DOI: 10.1056/NEJMoa071359.
- Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. The New England Journal Of Medicine 2007, 356: 1304-16. PMID: 17387129, DOI: 10.1056/NEJMoa070635.
- Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research And Opinion 2007, 23: 885-94. PMID: 17407645, DOI: 10.1185/030079907X182121.
- Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal 2016, 178: 135-44. PMID: 27502861, DOI: 10.1016/j.ahj.2016.05.010.
- Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal Of Medicine 2017, 376: 1517-1526. PMID: 28304227, DOI: 10.1056/NEJMoa1614062.
- Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal Of Medicine 2017, 376: 1527-1539. PMID: 28304242, DOI: 10.1056/NEJMoa1701488.
Patient Care Organizations